Statement by Chip Davis, President and CEO, AAM, on HHS Secretary Nominee Tom Price

WASHINGTON, DC (January 18, 2017) — “Congressman Price has a deep background and expertise in complicated health care issues and has been a leader in delivering high quality and affordable health care to all Americans. Balancing competition and innovation in the pharmaceutical sector is critical to ensuring affordable and accessible generic medicines and we look forward to working with Mr. Price should the Senate confirm his nomination.

Generic drugs are the foundation of any successful effort to lower health spending and increase patient access to affordable medicine. Generic medicines have saved Americans and taxpayers $1.46 trillion over the past ten years. Moreover, as we work together to preserve and strengthen Medicare and Medicaid, we will be sure to offer our policy ideas on how generic medicines can continue to provide massive savings to each critical program. Last year alone, generic medicines saved Medicare $67.6 billion, which translates to a savings of $1,737 per enrollee. For Medicaid, the savings were $32.7 billion, which translates to a savings of $450 per enrollee.

We stand ready to work with the President-elect, both parties in Congress, Rep. Price and his entire health care team to ensure that generic medicines continue to keep treatments within reach of all Americans.”

Chip Davis
President and CEO
Association for Accessible Medicines

CONTACT:
Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.